期刊文献+

四例伴t(3;3)的急性髓系白血病的临床和实验室分析 被引量:3

Clinical and laboratory investigation of four acute myeloid leukemia patients with t(3;3) translocation
原文传递
导出
摘要 目的 探讨伴t(3;3)的急性髓系白血病 (AML)的临床和实验室特征。方法 骨髓细胞直接法和 2 4h短期培养法制备染色体 ,用R显带技术进行细胞遗传学分析。结果  4例患者的染色体核型分析结果均有t(3;3)的异常 ,临床和血液学改变符合AML诊断。 4例化疗后均未获得完全缓解 ,中位生存期为 4 .5个月。结论 t(3;3)是一种少见的核型异常 ,多存在于髓系白血病 ,其临床预后差。 Objective To investigate the clinical and laboratory characteristics of four acute myeloid leukemia with t(3;3) translocation. Methods Bone marrow cell chromosome karyotype analysis were carried out with direct method and short-term culture and R-banding technique. Results Four AML patients with t(3;3) translocation were identified. They did not obtain complete remission after chemotherapy and the median survival time was 4.5 months. Conclusions t(3;3) translocation is a rare chromosome abnormality,which has mostly been found in myeloid leukemia and the prognosis of these patients is poor.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2004年第1期35-37,共3页 Chinese Journal of Hematology
基金 国家 8 63计划资助项目 (2 0 0 1AA2 2 70 71) 浙江省科技厅重点项目 (2 0 0 3C2 3 0 13 )
关键词 急性髓系白血病 染色体易位 骨髓增生异常综合征 细胞遗传学 R显带技术 Translocation Leukemia, myeloid, acute Myelodysplastic syndrome
  • 相关文献

同被引文献17

  • 1肖志坚,郝玉书.免疫表型分析与急性白血病诊断[J].中华血液学杂志,1997,18(1):53-54. 被引量:67
  • 2Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trail. The Medical Research Council Adult and Children's Leukaemia Working Parties [J]. Blood, 1998,92(7) :2322-2333.
  • 3Bench A J, Erber W N, Scott M A. Molecular genetic analysis of haematological malignancies : I. Acute leukaemias and myeloproliferative disorders [ J ]. Clin Lab Haematol, 2005,27 (3) : 148-171.
  • 4Weisser M, Haferlach C, Haferlach T, et al. Advanced age and high initial WBC influence the outcome of inv (3) (q21q26)/t (3;3) (q21;q26) positive AML [J]. Leuk Lymphoma,2007,48(11): 2145-2151.
  • 5Henning Walczak, Axel Bouchon. Tumor necrosis factor-related apoptosis inducing ligand retains its apoptosis-inducing capacity on Bcl-2 or Bcl-XLoverexpressing chemotherapy-resistance tumor cells [J]. Cancer Research, 2000,60: 3051~ 3057.
  • 6Chillon CM, Garcia Sanz R, Balanzategui A et al.Molecaular characterization of acute myeloblastic leukemia according to the new WHO classification:a different distribution in central-west spain [J]. Cancer Genet Cytogenet, 2000,122 (2) : 79.
  • 7Hiratake S,Azuma E,Nishiguchi Y et al. Treatment of multidrug-re-sistance murine leukemia with antisense mdrl oligocleoxynucleotides [J]. Biomed Pharmacother, 1997,51 (6 - 7): 276 - 283.
  • 8Perkins C,Kim CN,Fang CF et al. Arsenis induces apoptosis of multidrug resistance human myeloid leukemia cells that express Bcl/abl or overexpresson MDR,MRP,Bcl-2 or Bcl-XL[J]. Blood,2000,95(3):1014-1022.
  • 9Ng A, Taylor GM, Iden OB. Treatment-related leukemia-a clinical and scientific challenge[J]. Cancer Treatment Rev, 2000,26: 377 - 391.
  • 10Peiz F,Kroning H,Franke A et al. High reliability sensitivity of the BCR/ABL1D-FISH test for the detection of BCR/ABL rear-rangements[J]. Hasematologica, 2001,86 ( 2 ): 162.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部